Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 1
2017 2
2018 4
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Azacitidine Use for Myeloid Neoplasms.
El Fakih R, Komrokji R, Shaheen M, Almohareb F, Rasheed W, Hassanein M. El Fakih R, et al. Among authors: hassanein m. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):e147-e155. doi: 10.1016/j.clml.2018.02.005. Epub 2018 Feb 8. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29478947 Review.
Targeting FLT3 Mutations in Acute Myeloid Leukemia.
El Fakih R, Rasheed W, Hawsawi Y, Alsermani M, Hassanein M. El Fakih R, et al. Among authors: hassanein m. Cells. 2018 Jan 8;7(1):4. doi: 10.3390/cells7010004. Cells. 2018. PMID: 29316714 Free PMC article. Review.
The Evolution of Prognostic Factors in Multiple Myeloma.
Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. Hanbali A, et al. Among authors: hassanein m. Adv Hematol. 2017;2017:4812637. doi: 10.1155/2017/4812637. Epub 2017 Feb 21. Adv Hematol. 2017. PMID: 28321258 Free PMC article. Review.
FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M, Almahayni MH, Ahmed SO, Gaballa S, El Fakih R. Hassanein M, et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):543-549. doi: 10.1016/j.clml.2016.06.002. Epub 2016 Jun 25. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27450971 Review.
The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor-risk cytogenetic abnormalities.
Hassanein M, Fakih RE, Rasheed W, Ahmed S, Shaheen M, Chaudhri N, Alsharif F, Ahmed S, Hanbali A, AlShaibani A, Alfraih F, Alhayli S, Elhassan T, Alahmari A, Alzahrani H, Almohareb F, Aljurf M, Hashmi S. Hassanein M, et al. EJHaem. 2021 Mar 12;2(2):249-256. doi: 10.1002/jha2.136. eCollection 2021 May. EJHaem. 2021. PMID: 35845278 Free PMC article.
Outcomes and Long-Term Survival of Adolescent and Young Adult Patients Admitted to the Intensive Care Unit Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience of 152 Patients.
Solaiman OM, Elhassan T, Fakih RE, Mannan A, Alduhailib Z, Mahdali AA, Alzahrani H, Jamil M, Chaudhri N, Elhazmi A, Kolko M, Al-Sharif FZ, Alrbiaan A, Shaban M, Shaheen M, Salahuddin N, Alfraih FA, Altarifi AS, Hassanein M, Hosaini S, Alhashim N, Mohamed AA, Hanbali A, Aljanoubi AH, Al-Obaidi NR, Rasheed W, Maghrabi K, Almohareb F, Soubani A, Aljurf M, Ahmed SO. Solaiman OM, et al. Among authors: hassanein m. Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):110-119. doi: 10.56875/2589-0646.1114. Hematol Oncol Stem Cell Ther. 2024. PMID: 38560973
Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia: clinical characteristics, incidence, risk factors and outcomes.
Alhashim N, Aljurf M, Hassanein M, Chaudhri N, Hashmi S, El-Gohary G, Alsharif F, Alsermani M, Alhumaid M, Beihany AA, Shaheen M, Hanbali A, Alfraih F, Mohamed S, Alzahrani H, Elhassan T, Eldali A, Rasheed W, Ahmed S, Almohareb F, El Fakih R. Alhashim N, et al. Among authors: hassanein m. Bone Marrow Transplant. 2018 Jul;53(7):838-843. doi: 10.1038/s41409-018-0093-9. Epub 2018 Jan 25. Bone Marrow Transplant. 2018. PMID: 29371685